Drugs / Carbidopa
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Stalevo | — | 2003-10-17 | europa.eu ↗ |
| Approved | US (FDA) | SINEMET | — | 1975-05-02 | fda.gov ↗ |
Trials 71 · started per year
today
US approved 1975
EU approved 2003
1
2
1
2
5
2
1
2
4
2
1
4
1
4
6
4
4
2
2
4
5
1
5
2
3
1
1974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05471609 | Jun → Aug 2025 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT07442591 | Mar → Jun 2026 overdue | — | Shanghai WD Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06161220 | Oct → Dec 2023 | — | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05708274 | Jan 2023 → Oct 2025 | spinal cord injury | Bronx VA Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT05250141 | Feb 2022 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT05128175 | Oct 2021 → Jan 2022 | Parkinson disease | Shanghai WD Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04591535 | Sep 2020 → Mar 2021 | Parkinson disease | Hong Kong WD Pharmaceutical Co., Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04553978 | Sep 2020 → Mar 2021 | Parkinson disease | Hong Kong WD Pharmaceutical Co., Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04513340 | Aug → Sep 2020 | Parkinson disease | Hong Kong WD Pharmaceutical Co., Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03140956 | Apr → Jul 2017 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03055936 | Feb → Jun 2017 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02706977 | Jan 2016 → Aug 2019 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02554734 | Aug → Nov 2015 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02448914 | May → Jul 2015 | Parkinson disease | LobSor Pharmaceuticals AB | Completed | No outcome recorded |
| Phase 1 | NCT02486432 | Apr 2015 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02312232 | Nov 2014 → Feb 2015 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02096601 | Aug 2014 → Mar 2015 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01437293 | Aug 2010 → Apr 2012 | cocaine abuse | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT01484990 | Apr → Sep 2010 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00693862 | Dec 2006 → Apr 2008 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT02763839 | Apr → Jul 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06831500 | Jul 2025 → Nov 2026 expected | Parkinson disease, multiple system atrophy, parkinsonian type, orthostatic hypotension | Julien Bally | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06587217 | Oct 2024 → Apr 2025 | parkinsonian disorder | University of Michigan | Completed | No outcome recorded |
| Phase 1/2 | NCT06219915 | Mar → May 2024 | parkinsonian disorder | University of Michigan | Completed | No outcome recorded |
| Phase 1/2 | NCT04325503 | Feb 2021 → Jun 2022 | parkinsonian disorder | University of Michigan | Completed | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT00547911 | Oct 2007 → Apr 2013 | Parkinson disease, autonomic nervous system disorder, multiple system atrophy | National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00239564 | Oct 2005 → Dec 2007 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT05036473 | Nov 2021 → Dec 2022 | Parkinson disease | Shanghai WD Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04778176 | Jun 2021 → Jul 2022 | Parkinson disease | SynAgile Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02873351 | Sep 2019 → Dec 2020 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03541356 | May 2018 → Jun 2019 | Parkinson disease | Impel Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03197493 | Aug 2017 → Jul 2020 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Completed | No outcome recorded |
| Phase 2 | NCT02577523 | Dec 2015 → Dec 2016 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02271503 | Nov 2015 → Aug 2016 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02553265 | Sep 2015 → May 2019 | Riley-Day syndrome, baroreflex failure | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02080819 | Feb 2014 → Jan 2017 | cocaine dependence | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT01663935 | Oct 2012 → Apr 2018 | albinism, oculocutaneous albinism | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 2 | NCT00947037 | Aug 2012 | Parkinson disease | Intec Pharma Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01515410 | Jan → Sep 2012 | Parkinson disease | Depomed | Completed | No outcome recorded |
| Phase 2 | NCT01296464 | Feb → Jul 2011 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00983814 | Oct 2009 → May 2011 | attention deficit-hyperactivity disorder | Chelsea Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00918177 | Jul 2009 → Oct 2012 | Parkinson disease | Intec Pharma Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01399905 | Mar 2009 → Apr 2011 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT00562198 | Jan → Feb 2008 | Parkinson disease | Orion Corporation, Orion Pharma | Terminated | No outcome recorded |
| Phase 2 | NCT00218023 | Mar 2006 → Apr 2012 | cocaine abuse | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00253084 | Nov 2005 → Dec 2007 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00200447 | Mar → Sep 2004 | Parkinson disease | Molecular NeuroImaging | Completed | No outcome recorded |
| Phase 2 | NCT00218075 | Mar 2000 → Oct 2007 | cocaine abuse | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01468012 | Jul 2014 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00685919 | May 2008 → Jul 2020 | postural orthostatic tachycardia syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT04379050 | Jun 2020 → Apr 2026 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03462043 | Apr → Nov 2018 | Parkinson disease | NeuroDerm Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02615873 | Jul 2016 → Dec 2019 | Parkinson disease | Intec Pharma Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02605434 | Mar 2016 → Jul 2019 | Parkinson disease | Intec Pharma Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01736176 | Mar 2013 → Mar 2015 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01212484 | Dec 2009 → Feb 2012 | Riley-Day syndrome | NYU Langone Health | Completed | No outcome recorded |
| Phase 3 | NCT00134966 | Aug 2005 → Sep 2007 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00139880 | Jun → Aug 2005 | Parkinson disease | UCB Pharma | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT06765668 | Feb → Nov 2025 overdue | Parkinson disease | Impax Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 4 | NCT06236230 | Nov 2023 → Jun 2024 | Parkinson disease | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 4 | NCT04742348 | Feb → Aug 2023 | alcohol-related disorders | University of Washington | Withdrawn | No outcome recorded |
| Phase 4 | NCT04723147 | Jan 2021 → Oct 2023 | atypical depressive disorder, depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03761030 | Jan 2019 → Sep 2021 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT03111485 | May 2017 → Oct 2022 | Parkinson disease, obstructive sleep apnea syndrome | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 4 | NCT01683253 | Nov 2012 → Dec 2014 | impulse control disorder | Sandoz | Completed | No outcome recorded |
| Phase 4 | NCT00174239 | Jul 2004 → Sep 2005 | Parkinson disease | Pfizer | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05909267 | Jul 2023 → Jul 2026 overdue | major depressive disorder | Charite University, Berlin, Germany | Recruiting | No outcome recorded |
| — | NCT00129181 | Jan 2005 → Dec 2006 | Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
Also used as a comparator or background therapy in 70 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05132660 Background | Jul 2022 → Dec 2027 expected | diabetic retinopathy | VA Office of Research and Development | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT04244058 Background | Sep 2020 → May 2023 | cognitive disorder, traumatic brain injury | Weill Medical College of Cornell University | Suspended | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT04052776 Comparator | Sep 2020 → Oct 2023 | spinal cord injury | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT04246437 Background | Feb 2020 → Feb 2027 expected | Lewy body dementia, Parkinson disease, pure autonomic failure | Daniel Claassen | Recruiting | No outcome recorded |
| Phase 1 | NCT03929068 Comparator | May 2019 → Jul 2022 | amyotrophic lateral sclerosis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT03887884 Background | Mar → Jun 2019 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03266965 Background | Mar 2018 → Aug 2020 | multiple sclerosis | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT03496870 Background | Feb → Jul 2018 | Parkinson disease | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02633007 Background | Dec 2015 → Mar 2016 | asthma | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02633839 Background | Dec 2015 → Apr 2016 | — | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02116465 Comparator | Mar 2014 | — | Desitin Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01486628 Comparator | Apr → Nov 2012 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01519284 Background | Nov 2009 → Feb 2010 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00845000 Background | Apr 2009 → Apr 2010 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00505843 Background | May 2007 → Feb 2008 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02774564 Background | Sep → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07709741 Comparator | Jun 2026 → Jun 2027 expected | — | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07246278 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01229332 Comparator | Jan → Nov 2011 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT01026428 Background | Sep 2009 → Jul 2010 | Parkinson disease | Newron Pharmaceuticals SPA | Completed | No outcome recorded |
| Phase 1/2 | NCT00914602 Comparator | May 2009 → Jan 2010 | Parkinson disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT07001150 Comparator | May 2025 → May 2026 overdue | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06626152 Background | Aug 2024 → May 2026 overdue | major depressive disorder | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2 | NCT06614153 Comparator | May 2023 → Jan 2024 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05781711 Background | Jan 2023 → Jan 2025 | Parkinson disease | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT07444892 Background | Apr 2022 → Nov 2025 | diabetic retinopathy | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT04558112 Background | Feb 2021 → Dec 2023 overdue | post-traumatic stress disorder | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT03022318 Background | May 2017 → Dec 2019 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Completed | No outcome recorded |
| Phase 2 | NCT02764125 Background | Apr 2016 → Mar 2018 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02763137 Comparator | Jul 2014 → Oct 2015 | Parkinson disease | IRCCS San Raffaele Roma | Completed | No outcome recorded |
| Phase 2 | NCT01479127 Background | Oct 2011 → Jul 2012 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01171313 Background | Jul 2010 → Oct 2011 | Parkinson disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01568047 Background | Feb → Jun 2010 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT01568034 Background | Apr 2009 → Feb 2010 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00789672 Comparator | Jan → Sep 2009 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 2 | NCT01323374 Comparator | Jan 2009 → Oct 2011 | fibromyalgia | Chelsea Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00713583 Background | Jan 2008 → Dec 2011 | cocaine dependence | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00558337 Comparator | Nov 2007 → Dec 2008 | Parkinson disease | Osmotica Pharmaceutical US LLC | Completed | No outcome recorded |
| Phase 2 | NCT03103399 Background | Sep 2006 → Sep 2007 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07229651 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07229664 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06785298 Comparator | Dec 2024 → Dec 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06113640 Comparator | Nov 2023 → Nov 2026 expected | Parkinson disease | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04520178 Comparator | Jul 2020 → Jun 2026 overdue | spinal cord injury | University of Alberta | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04000919 Comparator | Jun 2019 → Jun 2023 | spinal cord injury | Jessica M D'Amico | Suspended | No outcome recorded |
| Phase 2/3 | NCT01429077 Comparator | Oct 2007 → Mar 2012 | aphasia, stroke disorder | Shirley Ryan AbilityLab | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT03735901 Comparator | Jun 2019 → Aug 2024 overdue | stroke disorder | University Hospital, Basel, Switzerland | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01568073 Background | Mar 2011 → Nov 2013 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01227655 Background | Mar 2011 → Jul 2012 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01190813 Comparator | Sep 2010 → Jan 2014 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00357994 Comparator | Jan 2009 → Oct 2011 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00099268 Comparator | Sep 2004 → Nov 2008 | Parkinson disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT06075771 Background | Nov 2023 → Jan 2027 expected | atypical depressive disorder, depressive disorder | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT06013956 Background | Aug 2023 → Jun 2028 expected | Parkinson disease | David Escobar | Recruiting | No outcome recorded |
| Phase 4 | NCT04952194 Comparator | Jan 2022 → Dec 2023 | Parkinson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04990284 Background | Nov 2021 → Apr 2023 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 4 | NCT04821830 Background | Feb 2020 → Apr 2024 | Parkinson disease | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT03115827 Background | Apr 2017 → Dec 2018 | Parkinson disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02513485 Comparator | Oct 2015 → Feb 2020 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02346630 Comparator | Mar 2015 → Mar 2017 | stroke disorder | Ross D. Zafonte, MD | Withdrawn | No outcome recorded |
| Phase 4 | NCT01951105 Comparator | Feb 2015 → Sep 2017 | subacute bursitis | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT00642356 Background | Mar 2008 → May 2009 | Parkinson disease | Novartis | Terminated | No outcome recorded |
| Phase 4 | NCT00391898 Background | Oct 2006 → Jun 2008 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00143026 Background | Jul 2005 → Jun 2006 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00219284 Background | Jan 2005 → Jul 2008 | Parkinson disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07614126 Background | Apr → Dec 2026 expected | CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy | University Hospital, Montpellier | Recruiting | No outcome recorded |
| — | NCT04590612 Comparator | Jan 2021 → Jan 2022 | Parkinson disease, depressive disorder | Western University, Canada | Unknown | No outcome recorded |
| — | NCT04054960 Comparator | Sep 2019 → Sep 2021 | Parkinson disease | Western University, Canada | Unknown | No outcome recorded |
| — | NCT01470859 Comparator | Dec 2011 → Aug 2014 | Parkinson disease | Huashan Hospital | Completed | No outcome recorded |
| — | NCT01218425 Background | Nov 2010 → Jun 2012 | — | Maastricht University Medical Center | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-28 | AbbVie | AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease abbvie.com ↗ |
| 2019-09-23 | AbbVie | AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders® abbvie.com ↗ |
| 2015-06-12 | AbbVie | AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders abbvie.com ↗ |
| 2015-01-12 | AbbVie | AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease abbvie.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 141 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carbidopa | “Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa...” NCT03761030 ↗139“To test whether Parcopa, a new Orally Disintegrating Tablet of Carbidopa-Levodopa, has a faster onset of action, changes in the UPDRS Motor Exam score at intervals after a...” NCT00139880 ↗ “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “CREXONT ER capsules will contain Carbidopa (CD)/Levodopa (LD) 35.0 milligrams (mg)/140 mg and/or CD/LD 52.5 mg/210.0 mg and/or CD/LD 70.0 mg/280 mg and/or CD/LD 87.5 mg/350 mg.” NCT06765668 ↗ “Treatment with L-dopa combined with a peripheral decarboxylase inhibitor (carbidopa) will be introduced gradually over a period of one year from the start of treatment.” NCT07614126 ↗ “A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each).” NCT05708274 ↗ “Participants will be administered a levodopa-carbidopa challenge, at a dosage of 150mg/37.5mg once daily for one week, followed by twice daily for one week.” NCT06626152 ↗ “Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).” NCT01026428 ↗ “Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients” NCT02763137 ↗ “Patients will receive tablets of generic 25 mg carbidopa/100 mg levodopa as the drug treatment.” NCT07444892 ↗ “Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.” NCT02706977 ↗ “two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)” NCT04558112 ↗ “IPX203 contains two different drugs called levodopa and carbidopa in one capsule.” NCT02271503 ↗ “IPX054 contains two different drugs called levodopa and carbidopa in one tablet.” NCT00253084 ↗ “IPX054 contains two different drugs called levodopa and carbidopa in one tablet.” NCT00239564 ↗ “L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration” NCT04990284 ↗ “Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide)” NCT03103399 ↗ “levodopa and carbidopa solution for subcutaneous administration” NCT01486628 ↗ “Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets” NCT02774564 ↗ “We will give 3 tablets of Levodopa-Carbidopa (100/25).” NCT04054960 ↗ “Long-acting levodopa: levodopa 200mg/ carbidopa 50mg” NCT03111485 ↗ “Sinemet CR 250' (Levodopa 200mg, and 50mg carbidopa)” NCT01470859 ↗ “WD-1603 extended-release carbidopa/levodopa tablets” NCT04553978 ↗ “Single oral dose of Carbidopa/Levodopa 25 mg/100 mg” NCT03887884 ↗ “a Liquid Formulation of Levodopa/Carbidopa (LD/CD)” NCT02096601 ↗ “Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100” NCT02763839 ↗ “Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg” NCT04244058 ↗ “72.5mg carbidopa (CD) and 230mg levodopa (LD)” NCT01515410 ↗ “Accordion Pill Carbidopa/Levodopa (AP-CD/LD)” NCT00947037 ↗ “800mg levodopa and 200mg carbidopa per day” NCT00713583 ↗ “Carbidopa-Levodopa Enteral Suspension.” NCT03462043 ↗ “administered with Lodosyn® (carbidopa)” NCT00914602 ↗ “25 mg carbidopa/100 mg levodopa” NCT05132660 ↗ “levodopa/carbidopa/entacapone” NCT02764125 ↗ “Carbidopa” NCT04000919 ↗ |
| Known as | Carbidopa and Levodopa Controlled Release Tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04952194 ↗ |
| Known as | carbidopa monohydrate | “TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).” NCT02448914 ↗ |
| Known as | ND0611 | “Subcutaneous Continuously-delivered Carbidopa Solution (ND0611)” NCT01229332 ↗ |
| Action | Inhibit | “carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase inhibitors'. It helps levodopa work more effectively by slowing the speed at which levodopa...” NCT00239564 ↗ |
| Route | Oral | “Orally Disintegrating Tablet” NCT00139880 ↗ |
| Target | DDC | “Carbidopa is a DOPA decarboxylase (DDC) inhibitor.” NCT01323374 ↗ |